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Abstract
Background: There has been a successful push towards parasitological diagnosis of malaria in Africa, mainly with rapid
diagnostic tests (mRDTs), which has reduced over-prescribing of artemisinin-based combination therapies (ACT) to
malaria test-negative patients. The effect on prescribing for test-positive patients has received much less attention.
Malaria infection in endemic Africa is often most dangerous for young children and those in low-transmission settings.
This study examined non-prescription of antimalarials for patients with malaria infection demonstrated by positive
mRDT results, and in particular these groups who are most vulnerable to poor outcomes if antimalarials are not given.
Methods: Analysis of data from 562,762 patients in 8 studies co-designed as part of the ACT Consortium, conducted
2007–2013 in children and adults, in Cameroon, Ghana, Nigeria, Tanzania, and Uganda, in a variety of public and
private health care sector settings, and across a range of malaria endemic zones.
Results: Of 106,039 patients with positive mRDT results (median age 6 years), 7426 (7.0%) were not prescribed an ACT
antimalarial. The proportion of mRDT-positive patients not prescribed ACT ranged across sites from 1.3 to 37.1%. For
patients under age 5 years, 3473/44,539 (7.8%) were not prescribed an ACT, compared with 3833/60,043 (6.4%) of
those aged ≥ 5 years. The proportion of < 5-year-olds not prescribed ACT ranged up to 41.8% across sites. The odds of
not being prescribed an ACT were 2–32 times higher for patients in settings with lower-transmission intensity (using
test positivity as a proxy) compared to areas of higher transmission. mRDT-positive children in low-transmission
settings were especially likely not to be prescribed ACT, with proportions untreated up to 70%. Of the 7426 mRDT-
positive patients not prescribed an ACT, 4121 (55.5%) were prescribed other, non-recommended non-ACT antimalarial
medications, and the remainder (44.5%) were prescribed no antimalarial.
Conclusions: In eight studies of mRDT implementation in five African countries, substantial proportions of patients
testing mRDT-positive were not prescribed an ACT antimalarial, and many were not prescribed an antimalarial at all.
Patients most vulnerable to serious outcomes, children < 5 years and those in low-transmission settings, were most
likely to not be prescribed antimalarials, and young children in low-transmission settings were least likely to be treated
for malaria. This major public health risk must be addressed in training and practice.
(Continued on next page)
© The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: shennae.oboyle@lshtm.ac.uk
1London School of Hygiene and Tropical Medicine, London, UK
Full list of author information is available at the end of the article
O’Boyle et al. BMC Medicine           (2020) 18:17 
https://doi.org/10.1186/s12916-019-1483-6
(Continued from previous page)
Trial registration: Reported in individual primary studies.
Keywords: Malaria, Diagnosis, Case management, Fever case management, Rapid diagnostic test, Prescribing,
Prescription, Antimalarial, ACT, Antibiotic
Background
Malaria remains among the top ten causes of death in many
African countries, and acute febrile illness is the most
common presentation in most African outpatient clinics [1].
Prompt antimalarial treatment with the recommended
artemisinin-based combination therapies (ACTs) [2] is
highly effective, and especially important in cases of Plasmo-
dium falciparummalaria which is responsible for the major-
ity of malaria-related deaths both globally and in Africa [3].
Whilst the probability of aquiring malaria increases with
transmission, in many endemic African settings, two
groups have been shown to be at particularly high risk of
mortality if they acquire malaria: young children (< 5
years) and children of any age in lower-transmission set-
tings where immunity to severe disease is acquired slowly
if at all [4]. Cerebral malaria in particular is more common
in low-transmission settings [5] often leading to higher
mortality rates. In both groups, mortality can be prevented
by effective antimalarials if diagnosed early (i.e. in out-
patient settings) and mortality in these children should be
close to zero if treated promptly when symptoms first
start. In contrast to semi-immune adults in high-
transmission settings, it is very unlikely that malaria para-
sitaemia is not relevant to the cause of the fever in young
children or those in low-transmission settings, making de-
layed or absent antimalarial treatment potentially fatal.
In 2010, the World Health Organization (WHO) updated
its guidelines to recommend universal parasitological con-
firmation of malaria before treatment [2]. This policy shift
aimed to encourage more rational use of antimalarials by
limiting over-diagnosis of malaria and over-prescription of
the newer, more expensive ACTs; promote diagnosis of
other febrile illnesses in patients without malaria; and slow
development of resistance to artemisinin and its partner
drugs [2]. The introduction of malaria rapid diagnostic tests
(mRDTs) has been key in increasing access to diagnostic
testing, particularly in settings where traditional microscopy
methods are not widely available [6]. Growing evidence
shows that parasitological diagnosis of malaria can be
achieved at the community level [7, 8] and in private health
care settings [9–13]. Thanks in large part to the introduc-
tion of mRDTs, diagnostic testing of suspected malaria
cases presenting to public health care facilities in the Afri-
can region has increased from 33% in 2010–2012 to 59%
overall, and higher in many sites, by 2015–2017 [14].
A number of mRDT evaluations have assessed impact
on case management, and in most settings, attention has
been focused on the potential for mRDT use to improve
targeting of antimalarials primarily by reducing over-
prescription—i.e. health workers adhere to negative test
results and do not prescribe antimalarials [7, 15, 16].
The impact on malaria test-positive patients, when re-
ported, has generated less concern; for example, a 2017
systematic review showed that in most studies that in-
vestigated the appropriateness of treatment following a
positive mRDT result, more than 95% of patients re-
ceived appropriate antimalarial medication, although
three studies showed that more than 10% of mRDT-
positive patients did not [17]. Whilst reducing unneces-
sary and inappropriate antimalarial use and identifying
non-malarial causes of fever is a major public health
goal, it remains essential that those who do have clinical
malaria are given timely and effective treatment.
The ACT Consortium, a global research partnership de-
signed to address core themes around malaria case man-
agement, conducted studies between 2007 and 2013 to
assess the impact of mRDT implementation across varied
epidemiological and health care contexts. In these studies,
the proportion of patients who had a positive mRDT but
were not prescribed an ACT varied widely [18]. Relatively
little is known about what might contribute to under-
prescription for test-positive patients. This paper presents
an analysis of ACT Consortium data, focusing specifically
on this potentially dangerous phenomenon which was pre-
viously identified across multiple settings [18, 19]. We aim
to help define the potential scale of under-prescription and
to identify factors associated with ACT non-prescription.
Specifically, this analysis examines non-prescription of
ACT antimalarials for mRDT-positive patients in two
groups that have not been examined but who are more vul-
nerable to poor outcomes: young children and individuals
in lower-transmission settings in whom significant immun-
ity is unlikely and mortality from untreated malaria is often
higher.
Methods
Studies included in the analysis
ACT Consortium studies were designed collaboratively
to form a multifaceted investigation of the impact of in-
terventions to improve the use of ACT antimalarials.
This analysis examines in more detail data on patients in
ACT Consortium study areas in Africa who tested posi-
tive for malaria by mRDT but who were not prescribed
ACT antimalarials [18, 19]. The primary studies were
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designed to measure the impact of mRDT implementation
on fever case management across a variety of settings.
Studies were included in this analysis if they collected data
on patient consultations for suspected malaria, evaluated
an intervention to implement mRDTs for use by health
care providers, and were conducted in sub-Saharan Africa
where the predominant malaria species is P. falciparum
and the recommended first-line therapy for malaria is an
ACT. The eight studies meeting these criteria are
described in Tables 1 and 2, including the abbreviation for
each study used throughout the text.
The eight studies included in this analysis were con-
ducted between 2007 and 2013 in Cameroon, Ghana,
Nigeria, Tanzania, and Uganda [20–27]. The studies
assessed the introduction of mRDTs among health care
providers in public health centres (Cam1, Ghan1, Tanz1,
Tanz2, Uga1), public and private facilities (Nige1), private
drug shops (Uga3), and community health programmes
(Uga2). Seven studies were designed as cluster randomised
trials, and one as an observational study carried out before
and after a national rollout of mRDTs in government-
sponsored primary care facilities (Tanz1). Most studies re-
corded data on all outpatients presenting with suspected
malaria, one study included only children aged under
6 years (Uga2), and two studies collected data on all out-
patient consultations (Tanz2, Uga1). For the purposes of
this analysis, patients not tested by mRDT, and those with
a negative mRDT result, were excluded. Data were
collected through provider-completed registers (Ghan1,
Uga1, Uga2, Uga3), patient exit interviews (Tanz1), or a
combination of both methods (Cam1, Nige1, Tanz2).
Outcome description
The analysis investigated the following: (i) proportion of
patients with a positive mRDT result who were not pre-
scribed ACT, (ii) patient and provider characteristics asso-
ciated with non-prescription of ACT for mRDT-positive
patients, and (iii) other medications prescribed for patients
with positive mRDT results who did not receive ACT.
Primary studies varied in design, context, and imple-
mentation, and therefore, not all variables considered for
this analysis were available for every study. Patient age and
sex, mRDT test result, and antimalarial prescription (ACT
and non-ACT) were recorded in all studies. Because of
the potential severity of malaria in children under 5 years
[28], patients were grouped into binary age categories of
under 5 years (< 5) or 5 years and over (≥ 5) to explore the
effect of age within each study setting. The exception was
Uga2: as Uga2 only included patients under 6 years, the
binary age groups for this study were categorised as under
1 year (< 1) and 1 year and over (≥ 1). Among children
under age 5 years, newborns and infants aged less than 12
months are most vulnerable to malaria, with increased risk
of rapid disease progression, severe anaemia, and
death [29].
Three studies were conducted in a single geographic area
(Ghan1, Uga1, Uga3), and five studies were conducted in
multiple locations (Cam1, Nige1, Tanz1, Tanz2, Uga2) with
differing malaria endemicity. To allow comparison of pre-
scribing practices within primary studies that were con-
ducted in more than one endemic zone, the proportion of
patients testing mRDT-positive (out of all patients tested)
at each site was used as a proxy for malaria endemicity.
Study settings were grouped into four categories: low posi-
tivity, 0 to 19.9% patient mRDT results positive (Tanz1,
Tanz2, Uga2); moderate-to-low positivity, 20.0 to 39.9%
(Cam1, Ghan1, Tanz2); moderate-to-high positivity, 40.0 to
54.9% (Nige1, Tanz1, Uga2); and high positivity, ≥ 55.0%
(Nige1, Uga1, Uga3). For simplicity, this proxy estimate is
referred to as “endemicity” in the remaining text.
Table 2 describes mRDT training and intervention de-
sign in each study site. In four primary studies, prescribers
in control arms did not use mRDTs and continued with
their current method of diagnosis (e.g. microscopy, or
clinical judgement; Ghan1, Uga1, Uga2, Uga3). These
arms were excluded from this analysis. However, a num-
ber of patients in the control arm of one study (Uga1: n =
8910) were tested using mRDTs not supplied through the
primary studies; analysis with and without this subgroup
found no difference in overall results.
All primary studies included at least one intervention
arm that introduced mRDTs, and some studies included an
additional intervention arm where mRDT introduction was
coupled with enhanced health worker training and ele-
ments of community involvement. For the analyses pre-
sented here, study interventions were re-categorised to
allow comparison of prescription practices across the train-
ing groups (Table 2): (i) no or basic training—mRDTs in-
troduced with either no training or basic health worker
training on how to perform the mRDT and interpret the re-
sult; (ii) enhanced training with behaviour change (BC
arm)—mRDTs introduced with training on mRDT use and
interpretation of results; and (iii) enhanced training with
behaviour change plus community sensitization (BC +CS
arm)—BC training as above plus an element of community
involvement. Uga2 and Uga3 included availability of rectal
artesunate (an artemisinin monotherapy) as a pre-referral
treatment; for the purposes of this analysis, patients who re-
ceived this treatment were dropped (n = 22 for Uga2, and
n = 45 for Uga3). Detailed descriptions of the specific inter-
ventions are included in individual study reports, and an
overview is presented in Burchett et al. [19].
Statistical analysis
The following variables were assessed as potential explana-
tory factors of outcomes of interest: sex, age, mRDT pro-
portion positive as a proxy for endemicity, health care
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sector, and intervention arm, where individual studies col-
lected data on these variables. Formal meta-analysis was
deemed inappropriate due to heterogeneity in study and
intervention design. Univariable and multivariable analyses
were conducted for each study separately, using logistic re-
gression with robust standard errors to account for cluster-
ing by the primary unit of sampling or randomisation.
Variables significantly associated with the outcome of inter-
est in univariable analyses (p value for Wald’s test < 0.05)
were included in multivariable analyses, along with age and
sex identified a priori. Statistical analyses were conducted in
STATA 14.0 (STATA Corp LP, College Station, TX).
Results
Patient characteristics for mRDT-positive patients
ACT Consortium studies recorded data on a total of 562,
762 outpatients presenting for health care in Africa. Of
these, 106,039 patients, median age 6 years (IQR 2 to 18
years), tested positive by mRDT. Of the mRDT-positive
patients, 7426 (7.0%) were not prescribed an ACT anti-
malarial. The proportion of mRDT-positive patients not
prescribed an ACT ranged across sites from 1.3% in Uga3
to 37.1% in Tanz1 (Additional file 1: Table S1).
Factors associated with ACT non-prescription for mRDT-
positive patients
Patient age
Overall, 3473/44,539 (7.8%) of patients younger than
5 years old were not prescribed an ACT antimalarial; this
proportion was 3833/60,043 (6.4%) for those aged 5 years
and older. The proportion varied by site, ranging from 1.3
(in Uga3) to 41.8% (in Tanz1) of mRDT-positive children
< 5 not given an ACT antimalarial (Table 3). In two of
eight study sites, the odds of ACT non-prescription were
Table 1 Description of study contexts
Study abbreviation
and country
Region (location) Study dates Endemicity setting (mRDT positivity) Number (%) of patients
with a positive mRDT
result that are under
5 years†
Health care
sectorNumber (%) of patients
with a positive mRDT
result of those tested
with mRDT
Category
Cam1 [20] Cameroon West Cameroon
(Bamenda)
October–December
2011
124/598 (20.7) Mod–low 34/124 (27.4) Public/mission
Central Cameroon
(Yaoundé)
145/390 (37.2) Mod–low 62/145 (42.8)
Ghan1 [21] Ghana Southeast Ghana
(Dangme West)
August 2007–December
2008
1308/3631 (36.0) Mod–low 407/1308 (31.1) Public
Nige1 [24] Nigeria South central
Nigeria (Udi)
July–December 2009;
June–December 2011
139/323 (43.0) Mod–high 16/137 (11.7) Public and
private retail
South central
Nigeria (Enugu)
442/788 (56.1) High 28/434 (6.5)
Tanz1 [23] Tanzania West Tanzania
(Mbeya)
May–October 2010;
April–July 2012
18/128 (14.1) Low 9/18 (50.0) Public
North Tanzania
(Mwanza)
46/278 (16.6) Low 34/46 (73.9)
Southeast
Tanzania (Mtwara)
173/367 (47.1) Mod–high 110/173 (63.6)
Tanz2 [22] Tanzania Northeast Tanzania
(Kilimanjaro)
September 2010–
January 2011
295/4334 (6.8) Low 51/294 (17.3) Public
Northeast Tanzania
(Tanga)
February 2011–March
2012
4105/12,963 (31.7) Mod–low 1429/4102 (34.8)
Uga1 [25] Uganda Southeast Uganda
(Tororo)
April 2011–March 2013 90,269/132,241 (68.3) High 37,339/88,875 (42.0) Public
Uga2 [26] Uganda Southwest Uganda
(Nyakishenyi)
January–December 2011 37/1128 (3.3) Low 4/35 (11.4)* Community
health worker
Southwest Uganda
(Bwambara)
3411/7632 (44.7) Mod–high 238/3342 (7.1)*
Uga3 [27] Uganda South central
Uganda (Mukono)
January–December 2011 5690/9987 (57.0) High 2239/5597 (40.0) Private retail
*Uga2 included only patients aged < 6 years; proportions presented for patients aged < 1 year
†Denominators vary to reported number testing positive by mRDT due to missing data for age. Nige1 (Udi: n = 2; Enugu: n = 8), Tanz2 (Kilimanjaro: n = 1; Tanga:
n = 3), Uga1 (n = 1394), Uga2 (Bwambara: n = 22), Uga3 (n = 28)
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Table 2 Description of study design and interventions
Project
site
Study design Primary study intervention arms Categorisation of intervention arms used in this study
Cam1 Cluster randomised
trial
Basic intervention: 1-day training on malaria diagnosis,
mRDTs, and prescribing antimalarials. Enhanced
intervention: additional 2-day training on adapting
to guideline changes, identifying alternative causes
of febrile illnesses, and communication skills. (Primary
study included control group with no training or
receipt of mRDTs)
No/basic training: includes those from the basic
intervention arm
BC arm: includes those from the enhanced training
arm
Ghan1 Individually
randomised trial
Intervention: 2-day training in sensitivity and specificity
of mRDTs, performing mRDTs, prescribing antimalarials,
identifying alternative causes of febrile illnesses, and
refresher on national guidelines. (Primary study included
control group practising current standard of care:
presumptive diagnosis (clinical setting) or microscopy
(microscopy setting))
No/basic training: includes those from the intervention
arm (NB comparison group did not use mRDTs, and
was therefore excluded from this analysis)
Nige1 Cluster randomised
trial
Control: half-day demonstration on use of mRDTs, plus
receipt of pictorial aid. Basic intervention: 2-day training
on performing mRDTs, prescribing antimalarials, and
communication skills. Enhanced intervention: additional
community sensitisation element including teacher/
student education for malaria awareness. (Primary
study also included a formative study)
No/basic training: includes those from the control arm
BC arm: includes those from the basic intervention
arm
BC + CS arm: includes those from the enhanced
intervention arm
Tanz1 Observational study
(during national rollout
of mRDTs)
Intervention: 2-day government training on performing
mRDTs, prescribing antimalarials, rationale for guideline
change, and identifying alternative causes of febrile
illnesses. (Primary study included baseline and endline
surveys for evaluation)
No/basic training: includes those that undertook
government training (NB comparison group did
not use mRDTs, and was therefore excluded from
this analysis)
Tanz2 Baseline survey
followed by cluster
randomised trial
Control: 2-day government training on performing mRDTs,
prescribing antimalarials, rationale for guideline change,
and identifying alternative causes of febrile illnesses.
Intervention: three half-day workshops on adapting to
and sustaining guideline changes, and communication
skills. Enhanced intervention: as above (intervention) plus
receipt of additional visual communication resources for
patients and facilities. (Primary study included a pilot study
with 1-day basic training on mRDT use)
No/basic training: includes those from control arm
BC arm: includes those from the intervention arm
BC + CS arm: includes those from the enhanced
intervention arm
Uga1 Cluster randomised
trial
Intervention: 2-day training on performing mRDTs,
prescribing antimalarials, identifying alternative causes of
febrile illnesses, and communication skills. (Primary study
included patients in the control group tested by mRDT if
already available in health care facility, but training on use
and interpretation of mRDTs not supplied by study)
No/basic training: includes those from the control arm
that were tested by mRDTs not supplied by the study
BC arm: includes those from the intervention arm
Uga2 Cluster randomised
trial
Intervention: 4-day training on performing and reading
mRDTs, prescribing antimalarials, dealing with negative
cases, communication skills, community sensitisation for
diagnostic testing, plus visual communication resources
for health care workers. (Primary study included control
group receiving 3-day training in malaria diagnosis and
referral (but not in use of mRDTs), and community
sensitisation for diagnostic testing)
BC + CS arm: includes those from the intervention
arm (NB comparison group did not use mRDTs,
and was therefore excluded from this analysis)
Uga3 Cluster randomised
trial
Intervention: 4-day training for drug shop vendors in
performing and reading mRDTs, prescribing antimalarials,
dealing with negative cases, communication skills, and
community sensitisation for diagnostic testing. (Primary
study included formative study, and control group
receiving 3-day training in malaria diagnosis and referral
(but not in use of mRDTs), and community sensitisation
for diagnostic testing)
BC + CS arm: includes those from the intervention
arm (NB comparison group did not use mRDTs,
and was therefore excluded from this analysis)
BC enhanced training arm with behaviour change component, BC + CS enhanced training arm with behaviour change and community sensitisation components
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significantly higher for younger children compared
with older patients (Ghan1 in those under 5 years,
and Uga2 in those under 12 months), with a trend to-
wards this association in three additional studies
(Cam1, Tanz1, and Uga1). The only exception was
Tanz2 where the odds of ACT non-prescription were
higher for older patients (Table 3).
Malaria endemicity (using mRDT positivity as a proxy)
Prescription practices were compared within primary
studies that included sites with varied levels of endem-
icity (Nige1, Tanz1, Tanz2, Uga2). In these studies, the
odds of not being prescribed an ACT were 2 to 32 times
higher for patients seeking care in lower-transmission
settings as compared to those seeking care in areas of
higher transmission (Table 4). Analysis of patient age
and endemicity suggested that ACT non-prescription is
particularly common for children under age five in
lower-transmission settings (Table 4); for example, in
Tanz1, 34/110 (31%) of mRDT-positive under-fives in
higher transmission settings were not prescribed
ACTs, whilst in low-transmission settings, this pro-
portion was 70%.
Other factors
In most studies, there was no evidence to suggest an associ-
ation between patient gender and ACT non-prescription.
The exception was Uga1, where female patients had 1.14
times the odds of not being prescribed ACT than male pa-
tients (p = 0.02). There were no differences observed when
comparing ACT non-prescription for mRDT-positive pa-
tients attending private versus public health facilities (in the
single study where it was possible to assess this), or for
those randomised to a no/basic training arm versus an en-
hanced intervention arm (Additional file 1: Table S2).
Prescription of other medications to mRDT-positive
patients
Of the 7426 mRDT-positive patients not prescribed an
ACT antimalarial, 4121 (55.5%) patients (ranging from
17.1 [in Tanz1] to 82.6% [in Tanz2] across study sites)
were prescribed other, non-ACT antimalarial medica-
tions (e.g. amodiaquine, chloroquine, or sulfadoxine-
pyrimethamine, as monotherapy or in combination). In
four studies (Cam1, Ghan1, Tanz2, Uga1), more than
half of the patients with a positive mRDT who were not
prescribed an ACT were prescribed a non-ACT antimal-
arial (Additional file 1: Table S1).
Table 3 Association of age with non-prescription of ACT among mRDT-positive patients
Project
site
Age
(years)
Total number (%)
of mRDT-positive
patients not
prescribed ACT by age*
Unadjusted Adjusted†
OR 95% CI‡ p value‡ OR 95% CI‡ p value‡
Cam1 < 5 27/94 (28.7) 1.00 Ref. 0.112 1.00 Ref. 0.089
≥ 5 35/166 (21.1) 0.66 0.40, 1.10 0.64 0.38, 1.07
Ghan1 < 5 15/406 (3.7) 1.00 Ref. < 0.001 1.00 Ref. < 0.001
≥ 5 14/899 (1.6) 0.41 0.30, 0.57 0.41 0.30, 0.57
Nige1 < 5 16/42 (38.1) 1.00 Ref. 0.218 1.00 Ref. 0.618
≥ 5 141/493 (28.6) 0.65 0.33, 1.29 0.85 0.46, 1.59
Tanz1 < 5 64/153 (41.8) 1.00 Ref. 0.049 1.00 Ref. 0.077
≥ 5 24/84 (28.6) 0.56 0.31, 1.00 0.55 0.28, 1.07
Tanz2 < 5 247/1480 (16.7) 1.00 Ref. < 0.001 1.00 Ref. < 0.001
≥ 5 700/2916 (24.0) 1.58 1.31, 1.90 1.42 1.15, 1.76
Uga1 < 5 3015/37,287 (8.1) 1.00 Ref. 0.081 1.00 Ref. 0.063
≥ 5 2862/51,473 (5.6) 0.67 0.43, 1.05 0.66 0.42, 1.02
Uga3 < 5 30/2239 (1.3) 1.00 Ref. 0.917 1.00 Ref. 0.898
≥ 5 44/3358 (1.3) 0.98 0.64, 1.50 0.97 0.63, 1.49
Uga2§ < 1 11/242 (4.6) 1.00 Ref. 0.017 1.00 Ref. 0.034
≥ 1 46/3135 (1.5) 0.31 0.12, 0.81 0.32 0.11, 0.92
*n is number of patients per study site (and endemicity setting) not prescribed ACT among all mRDT-positive patients with complete data for age, gender,
endemicity setting, sector, and intervention arm. Total number of mRDT-positive patients not prescribed ACT: N = 7291/104,454
†All adjusted models included age and gender as a priori variables and where sufficient data available (≥ 10 outcomes per cell), plus all other variables found
significant by univariate analyses (p < 0.05). Statistical models for each site vary in composition due to differences in study designs. Final regression models for
each site include the following variables: Cam1—gender and age; Ghan1—age only; Nige1—gender, age, sector, and endemicity setting; Tanz1—gender, age, and
endemicity setting; Tanz2—gender, age, and endemicity setting; Uga1—gender and age; Uga2—gender, age, and endemicity setting; and Uga3—gender and age
‡Confidence intervals and p value calculated using Wald’s test
§Uga2 age categories </≥ 1 due to primary study limited to patients aged under 6 years
O’Boyle et al. BMC Medicine           (2020) 18:17 Page 6 of 12
In mRDT-positive patients who were not prescribed an
ACT, at least one antibiotic was prescribed to 3882 (53.2%)
of these patients (from 12.4 [Nige1] to 57.0% [Uga1] across
study sites; this analysis excludes Uga2 where CHWs only
had antimalarials, and Uga3 where other medications were
not routinely recorded). A small proportion of patients
(n = 105, 1.7%) were prescribed only an antibiotic (0
[Ghan1, Tanz2] to 7% [Tanz1]) and no other medication.
Antipyretic prescription, with or without other medications,
ranged from 52.8 (Nige1) to 93.1% (Ghan1) across studies.
For 4.6 (Tanz2) to 35.2% (Tanz1) of patients, antipyretics
were the only medication prescribed. mRDT-positive pa-
tients prescribed no medication at all ranged from 0
(Ghan1) to 37.3% (Nige1) (Fig. 1). For comparison pur-
poses, the same analysis was conducted for mRDT-positive
patients who were prescribed ACT (n = 98,613). At least
one antibiotic was prescribed to 34,573 (38.5%) of these pa-
tients (from 16.0 [Ghan1] to 64.5% [Cam1] across study
Table 4 Association of endemicity and age with non-prescription of ACT among mRDT-positive patients
Project
site
mRDT
positivity
Age
(years)
Number (%) of
mRDT-positive
patients not
prescribed ACT
by proxy endemicity
setting*
Unadjusted Adjusted†
OR 95% CI‡ p value‡ OR 95% CI‡ p value‡
(i) Effect of endemicity setting on ACT non-prescription in baseline age group (< 5 years)
Nige1 High < 5 95/399 (23.8) 1.00 Ref. 0.004 1.00 Ref. 0.077
Mod–high 62/134 (46.3) 2.76 1.39, 5.45 1.98 0.93, 4.22
Tanz1 Mod–high < 5 47/173 (27.2) 1.00 Ref. 0.026 1.00 Ref. 0.027
Low 41/64 (64.1) 4.78 1.21, 18.93 4.80 1.19, 19.34
Tanz2 Mod–low < 5 770/4102 (18.8) 1.00 Ref. 0.001 1.00 Ref. < 0.001
Low 177/294 (60.2) 6.55 2.88, 14.85 6.22 2.70, 14.35
Uga2§ Mod–high < 1 46/3364 (1.4) 1.00 Ref. < 0.001 1.00 Ref. < 0.001
Low 11/35 (31.4) 33.1 11.88, 92.00 32.49 11.36, 92.92
(ii) Effect of age on ACT non-prescription in differing areas of endemicity
Nige1 High < 5 10/26 (38.5) 1.00 Ref. 0.052 1.00 Ref. 0.051
≥ 5 85/373 (22.8) 0.47 0.22, 1.01 0.47 0.22, 1.00
Mod–high‖ < 5 6/16 (37.5) – – – – – –
≥ 5 56/118 (47.5)
Tanz1 Mod–high < 5 34/110 (30.9) 1.00 Ref. 0.226 1.00 Ref. 0.221
≥ 5 13/63 (20.6) 0.58 0.24, 1.40 0.58 0.24, 1.39
Low < 5 30/43 (69.8) 1.00 Ref. 0.132 1.00 Ref. 0.124
≥ 5 11/21 (52.4) 0.48 0.18, 1.25 0.47 0.18, 1.23
Tanz2 Mod–high < 5 212/1429 (14.8) 1.00 Ref. < 0.001 1.00 Ref. < 0.001
≥ 5 558/2673 (20.9) 1.51 1.23, 1.86 1.51 1.23, 1.86
Low < 5 35/51 (68.6) 1.00 Ref. 0.117 1.00 Ref. 0.109
≥ 5 142/243 (58.4) 0.64 0.37, 1.12 0.67 0.43, 1.09
Uga2§ Mod–high < 1 10/238 (4.2) 1.00 Ref. 0.012 1.00 Ref. 0.013
≥ 1 36/3104 (1.2) 0.27 0.10, 0.75 0.27 0.09, 0.75
Low‖ < 1 1/4 (25.0) – – – – – –
≥ 1 10/31 (32.3)
*n is number of patients per study site not prescribed ACT among all mRDT-positive patients with complete data for age, gender, endemicity setting, sector, and
intervention arm. Total number of mRDT-positive patients not prescribed ACT: N = 7291/104,454
†All adjusted models included age and gender as a priori variables and where sufficient data available (≥ 10 outcomes per cell), plus all other variables found
significant by univariate analyses (p < 0.05). Statistical models for each site vary in composition due to differences in study designs. Final regression models for
each site include the following variables: Nige1—gender, age, sector, and endemicity; Tanz1—gender, age, and endemicity setting; Tanz2—gender, age, and
endemicity setting; Uga2—gender, age, and endemicity setting; Nige1 (high)—gender and age; Tanz1 (mod–high)—gender and age; Tanz1 (low)—gender and
age; Tanz2 (mod–high)—gender and age; Tanz2 (low)—gender, age, and intervention arm; and Uga2 (mod–high)—gender and age. Nige1 (mod–high) and Uga2
(low) had insufficient outcomes in binary age categories to undergo analysis
‡Confidence intervals and p value calculated using Wald’s test
§Uga2 age categories </≥ 1 due to primary study limited to patients aged under 6 years
‖Analysis not undertaken due to insufficient number of outcomes
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sites). Antipyretic prescription, with or without other medi-
cations, ranged from 73.6 (Cam1) to 97.9% (Tanz2) across
studies.
Factors associated with prescription of non-ACT
antimalarials and antibiotics
The analysis of factors associated with prescription of non-
ACT antimalarials was restricted to six studies due to low
outcome numbers in Ghan1 and Tanz1. Only one study,
Uga1, showed evidence of an association between patient
age and non-ACT antimalarial or antibiotic prescription. In
this study, children under age 5 years had higher odds of
being prescribed non-ACT antimalarials compared with
older patients (adjusted odds ratio [AOR] 0.20, p < 0.001)
(Additional file 1: Table S3). In contrast, older patients had
higher odds of being prescribed an antibiotic (AOR 1.58,
p < 0.001) (Additional file 1: Table S3). Neither health care
sector, nor mRDT positivity as a proxy for malaria endem-
icity, nor study intervention arm was associated with pre-
scription of non-ACT antimalarials or antibiotics.
Discussion
Cases of non-severe malaria should have a good outcome if
diagnosed and treated in a timely way with the recom-
mended ACT antimalarial; however, malaria is potentially
fatal if not treated appropriately. This is particularly true for
young children and patients in many low-transmission set-
tings, and in these groups, a proven parasitaemia is very
likely to be relevant to the clinical presentation. The current
analysis of data from more than 100,000 mRDT-positive
outpatients across several sites in 5 African countries found
widespread non-treatment with the recommended first-line
antimalarial treatment for malaria. This phenomenon was
more common in patient groups at highest risk of poor
outcomes for malaria infection: younger children (aged < 5
years, or infants < 12months in one study that enrolled
only children under age six) and patients of all ages in
lower-transmission settings. In some subgroups, up to 70%
of malaria-positive patients were not prescribed an ACT
antimalarial; this is potentially very dangerous. Malaria
treated early with effective drugs can usually be readily
cured; in vulnerable groups, if treated late, or not treated at
all, the outcome can be severe or fatal.
At the time of the studies in this analysis, an ACT was
recommended as the first-line treatment for malaria test-
positive patients in all study areas. Over recent years, sub-
stantial efforts have been made to target ACTs to patients
who have a parasite-based diagnosis of malaria. The devel-
opment and deployment of mRDTs in the African region
have increased access to confirmatory diagnostics, and in
many settings, use of mRDTs has reduced unnecessary
antimalarial prescription for mRDT-negative patients.
This study suggests, however, that the welcome reduction
of over-prescription of antimalarials to patients who test
negative for malaria has been accompanied by a reduction
in treatment for those who do have malaria, a potentially
life-threatening disease. In older patients in high-
transmission settings, asymptomatic parasitaemia is com-
mon, and finding parasites on testing febrile patients may
be coincidental, and not relevant to the aetiology of fever.
In low-transmission settings, and in young children prior
to the acquisition of appreciable immunity, finding
Fig. 1 Description of medications prescribed to mRDT-positive patients not prescribed ACT
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malaria parasites is almost always relevant (the patients
have malaria) and outcomes from not treating malaria are
potentially serious. It is, therefore, contrary to clinical logic
for non-treatment as found here, actually to be higher in
these groups.
The primary studies that contributed data to this analysis
were conducted between 2007 and 2013, which has two im-
plications. First, in common with most synthesis studies,
the data are a few years old and may not reflect current
practice. Second, the studies were conducted relatively early
in ACT implementation in routine care and at the time of
mRDT introduction (by design). It may take time for policy
change to translate fully into clinical practice, and whilst
there is some evidence that test adherence has improved in
some settings with strong supervision or training [30, 31],
other evidence suggests that under-treatment of malaria
test-positive patients persists (in proportions both similar
to, and higher than, those reported in this paper) [32–34].
Based on current data, it would be rash to assume that this
under-diagnosis and subsequent under-treatment has sim-
ply disappeared since 2013 without further intervention,
particularly as the problem of under-treatment in high-risk
groups has not been highlighted.
As part of mRDT introduction in the primary studies,
training messages advised health care workers to perform
a mRDT (or microscopy, where appropriate) and pre-
scribe ACT for positive results. In this analysis, just over
half of the test-positive patients who did not receive ACT
were prescribed a different, non-recommended antimalar-
ial; even more concerningly, overall, 44.5% were pre-
scribed no antimalarial medication at all. Furthermore,
when comparing antibiotic prescription among mRDT-
positive patients who were prescribed ACT and those who
were not, the proportions of antibiotic prescription were
substantially higher among those not prescribed ACT
(53.2% vs. 38.5%) [35]. There is no obvious clinical logic to
performing a diagnostic test and then ignoring a positive
result. mRDTs based on histidine-rich protein 2 (HRP2),
which are the predominant mRDT type used in most Afri-
can contexts including in the study areas analysed here,
may detect residual antigenemia persisting after a
cleared P. falciparum infection, but guidelines typic-
ally advise that providers only consider the possibility
of a false-positive mRDT result on this basis for a
short while after effective treatment of a confirmed
infection [2], which presumably would have been a
rare case presentation in the study populations. Simi-
larly, asymptomatic parasite carriage does occur, but
generally in high-transmission settings and among
older children and adults who have developed partial
immunity to malaria.
The primary ACT Consortium studies that provided
data for this analysis did not record health care workers’
reasons for prescribing certain drugs, and exploring this
further would require qualitative studies. Whilst it is
therefore not possible to draw direct conclusions from
these data about the causes of ACT non-prescription, a
number of possible explanatory factors were suggested by
Burchett et al. [19], including motivation to perform well
in a study context, stability of ACT supplies, and local
preferences for different types of antimalarials. More
broadly, other previous work has identified some factors
that are associated with non-adherence to test results and/
or treatment guidelines, including distrust in the test or
test result [36–39], patient demands or preferences for a
particular medication [19, 40–43], perceptions of low drug
efficacy [41], staff workload [44], financial incentives [42],
level of health care worker [41, 45, 46], affordability and
accessibility of non-recommended therapies [47, 48], and
rationing of medications [19, 49]. Stock-outs of weight-
specific drug packs can also lead to inappropriate pre-
scription of medications [45, 50], whilst lack of knowledge
on how to prescribe second-line drugs can lead to not pre-
scribing them at all [51]. The availability of antimalarials
has been shown to influence prescribing patterns [45, 47,
52], and health care workers are often restricted to pre-
scribing what is available to them. With the exception of
Tanz1 which evaluated “real-world” mRDT implementa-
tion, ACT stocks were generally maintained in the study
areas during the primary ACT Consortium studies; it is
possible, however, that some combination of these factors,
which are more common outside of optimal study condi-
tions, contributed to the prescribing behaviours seen in
this analysis. For example, the prescription of older, non-
ACT antimalarials may have persisted due to the contin-
ued availability of unused stock during the time period of
the studies, which was shortly after the introduction of
ACTs in many study areas.
Current guidelines to “test before treating” for malaria
[2] have been criticised for not accounting for variation
in malaria transmission and epidemiology [53]. Partial
immunity to malaria is more common among individ-
uals with higher levels of exposure, in whom fever symp-
toms may not be attributable to incidental parasitemia
detected by diagnostic tests [48, 49, 53].
A strength of this analysis is that it draws on data from
a large number of routine outpatient visits in eight pri-
mary studies in diverse malaria-endemic settings in Africa,
allowing analysis of prescribing practices across represen-
tative health care contexts. Although less commonly re-
ported, non-adherence in prescribing for mRDT-positive
patients has been acknowledged previously [18, 19]; this
analysis quantitatively explores a gap in knowledge about
prescribing practices by identifying specific populations to
which the risk of inappropriate treatment is greatest, and
demonstrating that the probability of under-treatment is
greatest in those in whom the risk of under-treatment is
also greatest.
O’Boyle et al. BMC Medicine           (2020) 18:17 Page 9 of 12
This analysis was subject to a number of limitations.
Firstly, because at the time of study initiation over-
diagnosis and over-treatment were almost universal,
non-adherence to positive mRDT results was not antic-
ipated when the ACT Consortium primary studies were
designed so the studies did not collect explanatory
qualitative information on this phenomenon. It is not
possible, therefore, to discern from these data why pro-
viders did not always prescribe according to positive
mRDT results. Similarly, a number of factors described
in previous reports (as summarised above) that may in-
fluence prescribing practices were not consistently
assessed in ACT Consortium studies and were not in-
cluded in this analysis. Thirdly, whilst the primary stud-
ies used similar methodologies, there were substantial
differences in study design and data collected, preclud-
ing formal meta-analysis. Furthermore, not all studies
recorded details of non-ACT medications prescribed,
limiting analysis of the secondary outcomes to data
from a smaller number of sites. We cannot exclude the
possibility that some patients had already started on
antimalarials at the time of presentation, or reported
having them at home, and so did not receive a prescrip-
tion. Finally, the proportion of patients testing positive
for malaria is only a crude proxy for malaria endem-
icity, but this is more likely to dilute any effect of en-
demicity rather than inflate it.
Febrile patients make up a large proportion of all health
care seeking in Africa, and until recently, empiric,
syndromic treatment was the norm, with inevitable mis-
diagnosis and, in particular, over-diagnosis of malaria. En-
couraging health workers to perform a malaria test, and to
adhere to negative test results, has been a remarkable pub-
lic health advance in malaria and fever case management.
However, these advances may come at a serious clinical
cost if true malaria cases in vulnerable groups at risk of
poor outcomes are left untreated. It is well known that
changing one health care practice can have unintended
consequences for other practices; for example, mRDT
introduction also tends to drive more prescription of anti-
biotics [35, 54], and it can also influence patient satisfac-
tion with care and affect the likelihood of treatment
seeking [54, 55]. The introduction of diagnostic technol-
ogy is not always straightforward, and future interventions
should emphasise the importance of following recommen-
dations for both test-positive and test-negative patients.
Case management guidelines need to be accessible, unam-
biguous, and consistently used, and must reinforce the
need to treat malaria test-positive patients with an ACT,
especially in vulnerable groups [56].
Conclusion
This analysis shows that in several settings, significant
numbers of malaria test-positive patients were not
prescribed antimalarials and in particular that this was
true for the vulnerable groups of young children and
those in low-transmission settings. Those responsible for
clinical services in malaria-endemic areas need to ensure
that all mRDT-positive patients are prescribed, and re-
ceive, locally recommended treatment, and that providers
have reliable access to effective antimalarials and the con-
fidence to trust mRDT results and prescribe accordingly.
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